Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.57 |
| ▸ | CPT1A | P50416 | 1/20 | 0.57 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3679660 | 1.00 | CPT2 (0.57) | CPT2CPT1ACPT1BSMPD1THRA | |
| SCHEMBL3692203 | 0.85 | CPT2 (0.46) | CPT2CPT1ACPT1B | |
| SCHEMBL3692200 | 0.85 | CPT2 (0.46) | CPT2CPT1ACPT1B | |
| SCHEMBL3679655 | 0.81 | CPT2 (0.63) | CPT2CPT1ACPT1BSMPD1THRA | |
| SCHEMBL4787986 | 0.78 | CPT2 (0.66) | CPT2CPT1ACPT1B | |
| SCHEMBL3679523 | 0.77 | GHSR (0.42) | CPT2CPT1ACPT1B | |
| SCHEMBL3679518 | 0.77 | GHSR (0.42) | CPT2CPT1ACPT1B | |
| SCHEMBL3688614 | 0.77 | CPT2 (0.70) | CPT2CPT1ACPT1BSMPD1THRA | |
| SCHEMBL3688617 | 0.77 | CPT2 (0.70) | CPT2CPT1ACPT1BSMPD1THRA | |
| SCHEMBL13410025 | 0.74 | CPT2 (0.52) | CPT2CPT1ACPT1BSMPD1THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.